Sonoma Pharmaceuticals (SNOA) Non-Current Deffered Revenue (2011 - 2025)

Sonoma Pharmaceuticals' Non-Current Deffered Revenue history runs 15 years deep, the most recent figure standing at $4000.0 for Q2 2025.

• In Q2 2025, Non-Current Deffered Revenue fell 93.75% year-over-year to $4000.0; the TTM figure through Jun 2025 stood at $4000.0 (down 93.75% YoY), while the FY2025 annual figure was $17000.0, down 80.46% from the prior year.
• Non-Current Deffered Revenue was $4000.0 for Q2 2025 at Sonoma Pharmaceuticals, down from $17000.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $229000.0 in Q1 2021 to a low of $4000.0 in Q2 2025.
• Historically, Non-Current Deffered Revenue has averaged $121277.8 across 5 years, with a median of $130000.0 in 2022.
• The sharpest annual moves came in 2021 and 2025: Non-Current Deffered Revenue retreated 6.25% in 2021, then tumbled 93.75% in 2025.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $190000.0 in 2021, then tumbled by 32.63% to $128000.0 in 2022, then dropped by 21.09% to $101000.0 in 2023, then slumped by 70.3% to $30000.0 in 2024, then tumbled by 86.67% to $4000.0 in 2025.
• The last three Non-Current Deffered Revenue figures came in at $4000.0 (Q2 2025), $17000.0 (Q1 2025), and $30000.0 (Q4 2024), per Business Quant data.